Lercanidipin Accord

Lercanidipine, the active ingredient in Lercanidipin Accord, is a calcium channel blocker presented as an oral tablet for oral administration. It is used to lower elevated blood pressure in adult patients with hypertension, helping to reduce cardiovascular risk.

GNH USA supplies Lercanidipin Accord as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide under strict quality standards. The product complies with EU regulatory requirements and is available for export to multiple regions. GNH USA's global network ensures reliable delivery and support for healthcare providers seeking consistent supply.

Lercanidipine is a calcium channel blocker indicated for the management of hypertension.

- Essential hypertension: lowers systolic and diastolic blood pressure in patients with primary hypertension. - Isolated systolic hypertension: helps control elevated systolic pressure, especially in older adults. - Hypertensive patients with cardiovascular risk: contributes to overall risk reduction when used with other antihypertensive agents.

Adverse reactions may occur with any antihypertensive therapy and should be monitored.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of ankles or lower limbs. - Dizziness or light‑headedness, especially after standing. - Tachycardia: increased heart rate. - Palpitations: sensation of irregular heartbeat.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat. - Severe hypotension: marked drop in blood pressure causing fainting. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: abnormal liver enzyme elevations. - Severe allergic reaction: rash, itching, or anaphylaxis.

Patients and prescribers should consider several safety aspects before initiating therapy. - Blood pressure monitoring: regularly assess to avoid excessive hypotension. - Hepatic impairment: use with caution and adjust dose if needed. - Elderly patients: start at lower dose and monitor for dizziness. - Concomitant antihypertensives: watch for additive blood‑pressure lowering effects. - Severe aortic stenosis: avoid use due to risk of reflex tachycardia. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lercanidipine may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can markedly increase plasma levels. - Grapefruit juice: may elevate drug concentration leading to hypotension.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce effectiveness. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt antihypertensive response. - Other antihypertensives (beta‑blockers, diuretics): may cause additive blood‑pressure lowering. - Lipid‑lowering agents (statins): monitor for increased statin exposure.